Invokana (BioDeep_00000858795)
代谢物信息卡片
Invokana
化学式: C48H52F2O11S2 (906.2918946000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O
InChI: /m11./s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:73272
- KEGGdrug: D09592
- PubChem: 24997615
- ChEMBL: CHEMBL2103841
- MeSH: Canagliflozin
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lindsey R VanDerStad, Emily C Wyatt, Roger A Vaughan. The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
Diabetic medicine : a journal of the British Diabetic Association.
2024 May; 41(5):e15271. doi:
10.1111/dme.15271. [PMID: 38140911] - Tian Gan, Qingzhu Wang, Yi Song, Mingwei Shao, Yanyan Zhao, Feng Guo, Fangyi Wei, Xunjie Fan, Wei Zhang, Yuanyuan Luo, Duo Chen, Shanshan Wang, Guijun Qin. Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease.
Molecular and cellular endocrinology.
2024 Mar; 582(?):112139. doi:
10.1016/j.mce.2023.112139. [PMID: 38128823] - Xiaoqing Xu, Dayang Wang, Huichai Pan, Jun Li, Bowu Li, Zhongchen He. Ketonuria in an adult with Prader-Willi syndrome and diabetes mellitus: A case report.
Medicine.
2024 Jan; 103(4):e37096. doi:
10.1097/md.0000000000037096. [PMID: 38277514] - Mingwei Shao, Duo Chen, Qingzhu Wang, Feng Guo, Fangyi Wei, Wei Zhang, Tian Gan, Yuanyuan Luo, Xunjie Fan, Peijie Du, Yanxia Liu, Xiaojun Ma, Gaofei Ren, Yi Song, Yanyan Zhao, Guijun Qin. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Diabetologia.
2024 Jan; ?(?):. doi:
10.1007/s00125-023-06078-0. [PMID: 38236410] - Jinsheng Li, Xueli Hou, Jinlong Xiao, Li Zhu, Yujie Deng, Ziyi Li, Zijian Zhao, Zhenghong Luo, Hao Wei. Synthesis of New Derivatives of Berberine Canagliflozin and Study of Their Antibacterial Activity and Mechanism.
Molecules (Basel, Switzerland).
2024 Jan; 29(1):. doi:
10.3390/molecules29010273. [PMID: 38202855] - Simo Liu, Jing Ke, Xiaotong Feng, Zongwei Wang, Xin Wang, Longyan Yang, Dong Zhao. The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.
Journal of diabetes research.
2024; 2024(?):2431441. doi:
10.1155/2024/2431441. [PMID: 38577301] - Chunru Yang, Cheng Xiao, Xiaojun Zhai, Jieying Liu, Miao Yu. SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease.
Journal of diabetes and its complications.
2023 Nov; 38(2):108652. doi:
10.1016/j.jdiacomp.2023.108652. [PMID: 38190779] - Xue Yang, Zhiwei He, Li Yuan, Wenbin Huang, Doudou Li, Pingping Xiang, Yu Chen, Guofang Chen, Chao Liu. Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial.
BMC endocrine disorders.
2023 Oct; 23(1):215. doi:
10.1186/s12902-023-01461-9. [PMID: 37814256] - Hongping Chen, Da Teng, Bowen Xu, Chunxiao Wang, Hua Wang, Wenjuan Jia, Lei Gong, Haibin Dong, Lin Zhong, Jun Yang. The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.
Journal of cardiovascular translational research.
2023 10; 16(5):999-1009. doi:
10.1007/s12265-023-10390-w. [PMID: 37126209] - Xinyi Xia, Miao Xu, Yunjie Gu, Yangxue Li, Li Li, Jun Yin. Low-carbohydrate diet in the treatment of type 2 diabetes mellitus (LoCaT): study protocol for a multicenter, randomized controlled trial.
Trials.
2023 Jun; 24(1):411. doi:
10.1186/s13063-023-07427-5. [PMID: 37337229] - Eiji Kutoh, Alexandra N Kuto, Eri Ozawa, Rumi Kurihara, Midori Akiyama. Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Drug research.
2023 Jun; 73(5):279-288. doi:
10.1055/a-2007-1893. [PMID: 36882112] - Satoko Kawarasaki, Honami Sawazaki, Hiroaki Iijima, Haruya Takahashi, Wataru Nomura, Kazuo Inoue, Teruo Kawada, Tsuyoshi Goto. Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression.
European journal of pharmacology.
2023 May; 947(?):175682. doi:
10.1016/j.ejphar.2023.175682. [PMID: 36965744] - Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway.
Hepatology communications.
2023 Mar; 7(3):e0045. doi:
10.1097/hc9.0000000000000045. [PMID: 36757426] - Wanqiu Zhang, Jinghua Lu, Yangyang Wang, Pengbo Sun, Tong Gao, Naihan Xu, Yaou Zhang, Weidong Xie. Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway.
International journal of molecular sciences.
2023 Jan; 24(1):. doi:
10.3390/ijms24010858. [PMID: 36614295] - Edoardo Biancalana, Giovanni Ceccarini, Silvia Magno, Valerio Ortenzi, Domenico Giannese, Ferruccio Santini, Anna Solini. Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report.
Frontiers in endocrinology.
2023; 14(?):1172468. doi:
10.3389/fendo.2023.1172468. [PMID: 37274321] - Emad H M Hassanein, Fayez M Saleh, Fares E M Ali, Eman K Rashwan, Ahmed M Atwa, Omnia A M Abd El-Ghafar. Neuroprotective effect of canagliflozin against cisplatin-induced cerebral cortex injury is mediated by regulation of HO-1/PPAR-γ, SIRT1/FOXO-3, JNK/AP-1, TLR4/iNOS, and Ang II/Ang 1-7 signals.
Immunopharmacology and immunotoxicology.
2022 Nov; ?(?):1-13. doi:
10.1080/08923973.2022.2143371. [PMID: 36326099] - Satoshi Miyamoto, Hiddo J L Heerspink, Dick de Zeeuw, Masao Toyoda, Daisuke Suzuki, Takashi Hatanaka, Tohru Nakamura, Shinji Kamei, Satoshi Murao, Kazuyuki Hida, Shinichiro Ando, Hiroaki Akai, Yasushi Takahashi, Daisuke Koya, Munehiro Kitada, Hisashi Sugano, Tomokazu Nunoue, Akihiko Nakamura, Motofumi Sasaki, Tatsuaki Nakatou, Kei Fujimoto, Daiji Kawanami, Takashi Wada, Nobuyuki Miyatake, Michihiro Yoshida, Kenichi Shikata. Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Diabetes, obesity & metabolism.
2022 Aug; 24(8):1429-1438. doi:
10.1111/dom.14731. [PMID: 35491532] - Sai Ma, Li-Li He, Guo-Rui Zhang, Qing-Juan Zuo, Zhong-Li Wang, Jian-Long Zhai, Ting-Ting Zhang, Yan Wang, Hui-Juan Ma, Yi-Fang Guo. Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction.
Naunyn-Schmiedeberg's archives of pharmacology.
2022 08; 395(8):945-962. doi:
10.1007/s00210-022-02243-1. [PMID: 35476142] - Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
European journal of preventive cardiology.
2022 Jul; 29(9):1352-1360. doi:
10.1093/eurjpc/zwab034. [PMID: 33659986] - Zhipeng Xu, Wenxin Hu, Bin Wang, Ting Xu, Jianning Wang, Dan Wei. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.
Yonsei medical journal.
2022 Jul; 63(7):619-631. doi:
10.3349/ymj.2022.63.7.619. [PMID: 35748073] - Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis M Ruilope, John Boletis, Robert Toto, Guillermo E Umpierrez, Christoph Wanner, Takashi Wada, Charlie Scott, Amer Joseph, Ike Ogbaa, Luke Roberts, Markus F Scheerer, George L Bakris. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2022 06; 37(7):1261-1269. doi:
10.1093/ndt/gfab336. [PMID: 34850173] - Jennifer Y Barraclough, Jie Yu, Gemma A Figtree, Vlado Perkovic, Hiddo J L Heerspink, Brendon L Neuen, Christopher P Cannon, Kenneth W Mahaffey, Aletta E Schutte, Bruce Neal, Clare Arnott. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
Diabetes, obesity & metabolism.
2022 06; 24(6):1072-1083. doi:
10.1111/dom.14671. [PMID: 35166429] - Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Cardiovascular diabetology.
2022 05; 21(1):67. doi:
10.1186/s12933-022-01508-6. [PMID: 35585590] - Wenhui Hao, Shiying Che, Jinsheng Li, Jingyi Luo, Wanqiu Zhang, Yang Chen, Zijian Zhao, Hao Wei, Weidong Xie. Synthesis of Berberine and Canagliflozin Chimera and Investigation into New Antibacterial Activity and Mechanisms.
Molecules (Basel, Switzerland).
2022 May; 27(9):. doi:
10.3390/molecules27092948. [PMID: 35566298] - Raphaëlle Corremans, Ellen Neven, Stuart Maudsley, Hanne Leysen, Marc E De Broe, Patrick C D'Haese, Benjamin A Vervaet, Anja Verhulst. Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
Kidney international.
2022 05; 101(5):929-944. doi:
10.1016/j.kint.2022.01.037. [PMID: 35271933] - Menno Pruijm, Olivier Phan, Anne Zanchi. Metformin versus SGLT-2 inhibitors: how low can we go?.
Kidney international.
2022 05; 101(5):874-877. doi:
10.1016/j.kint.2022.02.012. [PMID: 35461613] - John A Spertus, Mary C Birmingham, Michael Nassif, C V Damaraju, Antonio Abbate, Javed Butler, David E Lanfear, Ildiko Lingvay, Mikhail N Kosiborod, James L Januzzi. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
Nature medicine.
2022 04; 28(4):809-813. doi:
10.1038/s41591-022-01703-8. [PMID: 35228753] - Jie Yu, Jingwei Li, Phillip J Leaver, Clare Arnott, Mark D Huffman, Jacob A Udell, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, David R Matthews, Wayne Shaw, Norman Rosenthal, Bruce Neal, Gemma A Figtree. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Cardiovascular research.
2022 03; 118(4):1103-1114. doi:
10.1093/cvr/cvab128. [PMID: 33826709] - David M Charytan, Jie Yu, Meg J Jardine, Christopher P Cannon, Rajiv Agarwal, George Bakris, Tom Greene, Adeera Levin, Carol Pollock, Neil R Powe, Clare Arnott, Kenneth W Mahaffey. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2022 03; 17(3):361-373. doi:
10.2215/cjn.08980621. [PMID: 35063969] - Zirui Hao, Yue Sun, Guiping Li, Yuli Shen, Yingzhen Wen, Yan Liu. Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes.
BMC endocrine disorders.
2022 Feb; 22(1):37. doi:
10.1186/s12902-022-00949-0. [PMID: 35144596] - Muthiah Vaduganathan, Naveed Sattar, Jialin Xu, Javed Butler, Kenneth W Mahaffey, Bruce Neal, Wayne Shaw, Norman Rosenthal, Michael Pfeifer, Michael K Hansen, James L Januzzi. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
Journal of the American College of Cardiology.
2022 02; 79(5):432-444. doi:
10.1016/j.jacc.2021.11.027. [PMID: 35115099] - Hiddo J L Heerspink, Megumi Oshima, Hong Zhang, Jingwei Li, Rajiv Agarwal, George Capuano, David M Charytan, Jagriti Craig, Dick de Zeeuw, Gian Luca Di Tanna, Adeera Levin, Bruce Neal, Vlado Perkovic, David C Wheeler, Yshai Yavin, Meg J Jardine. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2022 02; 79(2):244-256.e1. doi:
10.1053/j.ajkd.2021.05.005. [PMID: 34029680] - Simke W Waijer, Taha Sen, Clare Arnott, Bruce Neal, Jos G W Kosterink, Kenneth W Mahaffey, Chirag R Parikh, Dick de Zeeuw, Vlado Perkovic, Brendon L Neuen, Steven G Coca, Michael K Hansen, Ron T Gansevoort, Hiddo J L Heerspink. Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.
Clinical journal of the American Society of Nephrology : CJASN.
2022 02; 17(2):251-259. doi:
10.2215/cjn.08780621. [PMID: 34876454] - F P Zhang, X Jiang. The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
2022 Feb; 73(1):. doi:
10.26402/jpp.2022.1.06. [PMID: 35639038] - Qingjuan Zuo, Guorui Zhang, Lili He, Sai Ma, Huijuan Ma, Jianlong Zhai, Zhongli Wang, Tingting Zhang, Yan Wang, Yifang Guo. Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice.
Drug design, development and therapy.
2022; 16(?):4161-4177. doi:
10.2147/dddt.s388823. [PMID: 36510490] - Takashi Wada, Kazumi Mori-Anai, Yutaka Kawaguchi, Hideyuki Katsumata, Hidetaka Tsuda, Mitsutaka Iida, Kenji Arakawa, Meg J Jardine. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Journal of diabetes investigation.
2022 Jan; 13(1):54-64. doi:
10.1111/jdi.13624. [PMID: 34212533] - Jiaqi Zhang, Chuan Xing, Xiangyi Cheng, Bing He. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Frontiers in endocrinology.
2022; 13(?):1003238. doi:
10.3389/fendo.2022.1003238. [PMID: 36147577] - Shuqin Du, Hanqiang Shi, Lie Xiong, Ping Wang, Yanbo Shi. Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy.
Frontiers in endocrinology.
2022; 13(?):1011669. doi:
10.3389/fendo.2022.1011669. [PMID: 36313744] - Christian W Mende. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
Advances in therapy.
2022 01; 39(1):148-164. doi:
10.1007/s12325-021-01994-2. [PMID: 34846711] - Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan, Amirhossein Sahebkar. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Journal of diabetes research.
2022; 2022(?):7520632. doi:
10.1155/2022/7520632. [PMID: 35224108] - Matthew R Weir, Jagadish Gogate, C V Damaraju, Ricardo Correa-Rotter, Kenneth W Mahaffey. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
Diabetes, obesity & metabolism.
2022 01; 24(1):12-20. doi:
10.1111/dom.14539. [PMID: 34463423] - Nobuya Inagaki, Masaomi Nangaku, Yasushi Sakata, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki, Koume Hamada. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Advances in therapy.
2022 01; 39(1):674-691. doi:
10.1007/s12325-021-01984-4. [PMID: 34853985] - David Lam, Girish N Nadkarni, Gohar Mosoyan, Bruce Neal, Kenneth W Mahaffey, Norman Rosenthal, Michael K Hansen, Hiddo J L Heerspink, Fergus Fleming, Steven G Coca. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
American journal of nephrology.
2022; 53(1):21-31. doi:
10.1159/000519920. [PMID: 35016188] - Brendon L Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George Bakris, Christopher P Cannon, David M Charytan, Robert Edwards, Jose L Górriz, Meg J Jardine, Adeera Levin, Bruce Neal, Luca De Nicola, Carol Pollock, Norman Rosenthal, David C Wheeler, Kenneth W Mahaffey, Hiddo J L Heerspink. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
European heart journal.
2021 12; 42(48):4891-4901. doi:
10.1093/eurheartj/ehab497. [PMID: 34423370] - Taha Sen, Jingwei Li, Brendon L Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Wayne Shaw, William Canovatchel, Michael K Hansen, Hiddo J L Heerspink. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
Journal of the American Heart Association.
2021 12; 10(23):e021661. doi:
10.1161/jaha.121.021661. [PMID: 34854308] - Ikuro Matsuba, Masahiro Takihata, Masahiko Takai, Hajime Maeda, Akira Kubota, Kotaro Iemitsu, Shinichi Umezawa, Mitsuo Obana, Mizuki Kaneshiro, Takehiro Kawata, Tetsuo Takuma, Hiroshi Takeda, Hideo Machimura, Atsuko Mokubo, Tetsuya Motomiya, Taro Asakura, Taisuke Kikuchi, Yoko Matsuzawa, Shogo Ito, Masaaki Miyakawa, Yasuo Terauchi, Akira Kanamori. Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2021 12; 23(12):2614-2622. doi:
10.1111/dom.14508. [PMID: 34338409] - Sjoukje van der Hoek, Inês F Antunes, Khaled A Attia, Olivier Jacquet, Andre Heeres, Marian Bulthuis, Rolf Zijlma, Hendrikus H Boersma, Harry van Goor, Ton J Visser, Hiddo J L Heerspink, Philip H Elsinga, Jasper Stevens. GMP Compliant Synthesis of [18F]Canagliflozin, a Novel PET Tracer for the Sodium-Glucose Cotransporter 2.
Journal of medicinal chemistry.
2021 11; 64(22):16641-16649. doi:
10.1021/acs.jmedchem.1c01269. [PMID: 34748702] - Taichi Minami, Akiko Kameda, Yasuo Terauchi. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Expert opinion on pharmacotherapy.
2021 Nov; 22(16):2087-2094. doi:
10.1080/14656566.2021.1939675. [PMID: 34114925] - Tamara K Young, Jing-Wei Li, Amy Kang, Hiddo J L Heerspink, Carinna Hockham, Clare Arnott, Brendon L Neuen, Sophia Zoungas, Kenneth W Mahaffey, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Bruce Neal, Meg Jardine. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.
Diabetologia.
2021 11; 64(11):2402-2414. doi:
10.1007/s00125-021-05524-1. [PMID: 34448033] - Maka Siamashvili, Stephen N Davis. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
Expert opinion on pharmacotherapy.
2021 Nov; 22(16):2181-2198. doi:
10.1080/14656566.2021.1967320. [PMID: 34388350] - Keshav Kumar, Tapan Behl, Arun Kumar, Sandeep Arora. SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
Current molecular pharmacology.
2021 10; 14(4):487-497. doi:
10.2174/1874467213666201012161439. [PMID: 33045972] - Taha Sen, Jingwei Li, Brendon L Neuen, Bruce Neal, Clare Arnott, Chirag R Parikh, Steven G Coca, Vlado Perkovic, Kenneth W Mahaffey, Yshai Yavin, Norman Rosenthal, Michael K Hansen, Hiddo J L Heerspink. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Diabetologia.
2021 10; 64(10):2147-2158. doi:
10.1007/s00125-021-05512-5. [PMID: 34415356] - Karan Matharu, Kiran Chana, Charles J Ferro, Alan M Jones. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
Pharmacology research & perspectives.
2021 10; 9(5):e00867. doi:
10.1002/prp2.867. [PMID: 34586753] - Cheol Son, Hisashi Makino, Masato Kasahara, Tomohiro Tanaka, Kunihiro Nishimura, S Taneda, Takeshi Nishimura, Shu Kasama, Yoshihiro Ogawa, Yoshihiro Miyamoto, Kiminori Hosoda. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
Diabetes research and clinical practice.
2021 Oct; 180(?):109037. doi:
10.1016/j.diabres.2021.109037. [PMID: 34481910] - Nora A Ashry, Rania R Abdelaziz, Ghada M Suddek, Mohamed A Saleh. Canagliflozin ameliorates aortic and hepatic dysfunction in dietary-induced hypercholesterolemia in the rabbit.
Life sciences.
2021 09; 280(?):119731. doi:
10.1016/j.lfs.2021.119731. [PMID: 34144054] - Saijun Zhou, YuLing Zhang, TongDan Wang, Shuai Huang, Siyi Gong, Junmei Wang, Pei Yu. Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function.
Diabetes & metabolism.
2021 09; 47(5):101274. doi:
10.1016/j.diabet.2021.101274. [PMID: 34481963] - Dave L Dixon, Hayley E Billingsley, Justin M Canada, Cory R Trankle, Dinesh Kadariya, Richard Cooke, Linda Hart, Benjamin Van Tassell, Antonio Abbate, Salvatore Carbone. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
Journal of cardiovascular pharmacology.
2021 09; 78(3):407-410. doi:
10.1097/fjc.0000000000001083. [PMID: 34132690] - Katherine M Wang, JingWei Li, Vivek Bhalla, Meg J Jardine, Bruce Neal, Dick de Zeeuw, Greg Fulcher, Vlado Perkovic, Kenneth W Mahaffey, Tara I Chang. Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.
Endocrinology, diabetes & metabolism.
2021 Jul; 4(3):e00247. doi:
10.1002/edm2.247. [PMID: 34277971] - Clare Arnott, Jing-Wei Li, Christopher P Cannon, Dick de Zeeuw, Brendon L Neuen, Hiddo J L Heerspink, David M Charytan, Anubha Agarwal, Mark D Huffman, Gemma A Figtree, George Bakris, Tara I-Hsin Chang, Kent Feng, Norman Rosenthal, Bernard Zinman, Meg J Jardine, Vlado Perkovic, Bruce Neal, Kenneth W Mahaffey. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
Diabetes, obesity & metabolism.
2021 07; 23(7):1652-1659. doi:
10.1111/dom.14386. [PMID: 33769679] - Marine Angé, Julien De Poortere, Audrey Ginion, Sylvain Battault, Mélanie Dechamps, Giulio G Muccioli, Martin Roumain, Johann Morelle, Sébastien Druart, Thomas Mathivet, Luc Bertrand, Diego Castanares-Zapatero, Sandrine Horman, Christophe Beauloye. Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK.
Scientific reports.
2021 07; 11(1):13700. doi:
10.1038/s41598-021-93156-1. [PMID: 34211080] - Shailendra Kumar Singh, Rina Singh, Satya Prakesh Singh. A Perfect Beta-Blocker for Kidney: Sglt-2 Inhibitor.
The Journal of the Association of Physicians of India.
2021 Jul; 69(7):11-12. doi:
NULL. [PMID: 34431284] - Yaoyun Niu, Yang Chen, Pengbo Sun, Yangyang Wang, Jingyi Luo, Yipei Ding, Weidong Xie. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment.
International immunopharmacology.
2021 Jul; 96(?):107773. doi:
10.1016/j.intimp.2021.107773. [PMID: 34020392] - Jean-Michel Halimi. [SGLT2 inhibitors: A new era for our patients].
Nephrologie & therapeutique.
2021 Jun; 17(3):143-148. doi:
10.1016/j.nephro.2020.12.006. [PMID: 33773943] - Panagiotis-Nikolaos Lalagkas, Georgios Poulentzas, Christos Kontogiorgis, Antonios Douros. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence.
Expert opinion on drug metabolism & toxicology.
2021 Jun; 17(6):697-705. doi:
10.1080/17425255.2021.1921735. [PMID: 33888031] - Nan Ye, Meg J Jardine, Megumi Oshima, Carinna Hockham, Hiddo J L Heerspink, Rajiv Agarwal, George Bakris, Aletta E Schutte, Clare Arnott, Tara I Chang, Jose L Górriz, Christopher P Cannon, David M Charytan, Dick de Zeeuw, Adeera Levin, Kenneth W Mahaffey, Bruce Neal, Carol Pollock, David C Wheeler, Gian Luca Di Tanna, Hong Cheng, Vlado Perkovic, Brendon L Neuen. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation.
2021 05; 143(18):1735-1749. doi:
10.1161/circulationaha.120.048740. [PMID: 33554616] - Zien Zhou, Meg J Jardine, Qiang Li, Brendon L Neuen, Christopher P Cannon, Dick de Zeeuw, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Vlado Perkovic, Bruce Neal, Richard I Lindley. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Stroke.
2021 05; 52(5):1545-1556. doi:
10.1161/strokeaha.120.031623. [PMID: 33874750] - Vivencio Barrios, Carlos Escobar. Canagliflozin: metabolic, cardiovascular and renal protection.
Future cardiology.
2021 05; 17(3):443-458. doi:
10.2217/fca-2020-0192. [PMID: 33538620] - Mouhamed Nashawi, Omar Sheikh, Ayman Battisha, Abdullah Ghali, Robert Chilton. Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors.
Heart failure reviews.
2021 05; 26(3):643-652. doi:
10.1007/s10741-020-10046-w. [PMID: 33169337] - Megumi Oshima, Meg J Jardine, Rajiv Agarwal, George Bakris, Christopher P Cannon, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Adeera Levin, Soo Kun Lim, Kenneth W Mahaffey, Bruce Neal, Carol Pollock, Norman Rosenthal, David C Wheeler, Hong Zhang, Bernard Zinman, Vlado Perkovic, Hiddo J L Heerspink. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Kidney international.
2021 04; 99(4):999-1009. doi:
10.1016/j.kint.2020.10.042. [PMID: 33316282] - Lampros Chrysavgis, Alkistis-Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Journal of gastroenterology and hepatology.
2021 Apr; 36(4):893-909. doi:
10.1111/jgh.15202. [PMID: 33439540] - Maurice Laville. Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation.
Kidney international.
2021 04; 99(4):814-816. doi:
10.1016/j.kint.2020.12.033. [PMID: 33745548] - Jie Yu, Clare Arnott, Brendon L Neuen, Hiddo L Heersprink, Kenneth W Mahaffey, Christopher P Cannon, Sadiya S Khan, Abigail S Baldridge, Sanjiv J Shah, Yuli Huang, Chao Li, Gemma A Figtree, Vlado Perkovic, Meg J Jardine, Bruce Neal, Mark D Huffman. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
ESC heart failure.
2021 04; 8(2):1482-1493. doi:
10.1002/ehf2.13236. [PMID: 33595905] - Margaret Nalugo, Nikolai Harroun, Chenglong Li, Larisa Belaygorod, Clay F Semenkovich, Mohamed A Zayed. Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes.
Vascular medicine (London, England).
2021 04; 26(2):131-138. doi:
10.1177/1358863x20961153. [PMID: 33095685] - Yi-Ling Zhou, Yong-Gang Zhang, Rui Zhang, You-Lian Zhou, Nan Li, Mi-Ye Wang, Hao-Ming Tian, She-Yu Li. Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital.
Chinese medical journal.
2021 Mar; 134(11):1317-1323. doi:
10.1097/cm9.0000000000001407. [PMID: 33734138] - Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, Carinna Hockham, Qiang Li, Rajiv Agarwal, George L Bakris, Christopher P Cannon, David M Charytan, Tom Greene, Adeera Levin, Jing-Wei Li, Brendon L Neuen, Bruce Neal, Richard Oh, Megumi Oshima, Carol Pollock, David C Wheeler, Dick de Zeeuw, Hong Zhang, Bernard Zinman, Kenneth W Mahaffey, Vlado Perkovic. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Clinical journal of the American Society of Nephrology : CJASN.
2021 03; 16(3):384-395. doi:
10.2215/cjn.15260920. [PMID: 33619120] - Ashish Sarraju, JingWei Li, Christopher P Cannon, Tara I Chang, Rajiv Agarwal, George Bakris, David M Charytan, Dick de Zeeuw, Tom Greene, Hiddo J L Heerspink, Adeera Levin, Bruce Neal, Carol Pollock, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Vlado Perkovic, Meg Jardine, Kenneth W Mahaffey. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
American heart journal.
2021 03; 233(?):141-148. doi:
10.1016/j.ahj.2020.12.008. [PMID: 33358942] - John A Spertus, Mary C Birmingham, Javed Butler, Ildiko Lingvay, David E Lanfear, Antonio Abbate, Mikhail L Kosiborod, Christina Fawcett, Paul Burton, C V Damaraju, James L Januzzi, John Whang. Novel Trial Design: CHIEF-HF.
Circulation. Heart failure.
2021 03; 14(3):e007767. doi:
10.1161/circheartfailure.120.007767. [PMID: 33724883] - Xiao-Nan Wang, Ying Li, Lu Meng, Cong-Yang Ding, Zhan-Jun Dong. Evaluation of influence of telmisartan on the pharmacokinetics and tissue distribution of canagliflozin in rats and mice.
Annals of palliative medicine.
2021 Mar; 10(3):3086-3096. doi:
10.21037/apm-21-65. [PMID: 33752434] - Daniël H van Raalte, Petter Bjornstad, Hiddo J L Heerspink, Frederik Persson, David Z I Cherney. Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.
Kidney international.
2021 03; 99(3):768-770. doi:
10.1016/j.kint.2020.12.006. [PMID: 33637205] - Seshagiri Rao Nandula, Nabanita Kundu, Hassan B Awal, Beda Brichacek, Mona Fakhri, Nikhila Aimalla, Adrian Elzarki, Richard L Amdur, Sabyasachi Sen. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
Cardiovascular diabetology.
2021 02; 20(1):44. doi:
10.1186/s12933-021-01235-4. [PMID: 33581737] - James L Januzzi, Javed Butler, Naveed Sattar, Jialin Xu, Wayne Shaw, Norman Rosenthal, Michael Pfeifer, Kenneth W Mahaffey, Bruce Neal, Michael K Hansen. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
Diabetes care.
2021 01; 44(1):210-216. doi:
10.2337/dc20-1889. [PMID: 33158949] - Shiqi Wang, Yasong Ding, Ruoyao Dong, Hongyun Wang, Lingdi Yin, Shengnan Meng. Canagliflozin Improves Liver Function in Rats by Upregulating Asparagine Synthetase.
Pharmacology.
2021; 106(11-12):606-615. doi:
10.1159/000518492. [PMID: 34515223] - Dilpreet Singh, Ashok K Tiwary, Tejwant Singh Kang, Neena Bedi. Polymeric Precipitation Inhibitor Based Supersaturable Self-microemulsifying Drug Delivery System of Canagliflozin: Optimization and Evaluation.
Current drug delivery.
2021; 18(9):1352-1367. doi:
10.2174/1567201818666210217155909. [PMID: 33596805] - Yingnan Zhao, Yanping Li, Qinhui Liu, Qin Tang, Zijing Zhang, Jinhang Zhang, Cuiyuan Huang, Hui Huang, Guorong Zhang, Jian Zhou, Jiamin Yan, Yan Xia, Zhiyong Zhang, Jinhan He. Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway.
Drug design, development and therapy.
2021; 15(?):2117-2128. doi:
10.2147/dddt.s306367. [PMID: 34040350] - Debmalya Sanyal, Anirban Majumder, Sujoy Ghosh, Kaushik Pandit. Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer.
Diabetes & metabolic syndrome.
2021 Jan; 15(1):385-389. doi:
10.1016/j.dsx.2021.01.011. [PMID: 33548908] - Andreea Ciudin, Marta Sánchez, Irene Hernandez, Efrain Cordero, Enzamaria Fidilio, Marta Comas, Carla Gonzalez, Natividad Lopez, Ramon Vilallonga, Marina Giralt, Roser Ferrer, Cristina Hernández, Rafael Simó. Canagliflozin: A New Therapeutic Option in Patients That Present Postprandial Hyperinsulinemic Hypoglycemia after Roux-en-Y Gastric Bypass: A Pilot Study.
Obesity facts.
2021; 14(3):291-297. doi:
10.1159/000515598. [PMID: 33965935] - Christoph Wanner, Kai Lopau. What Is the Utility of KDIGO Criteria to Identify High-Risk Populations?.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 01; 77(1):7-8. doi:
10.1053/j.ajkd.2020.10.002. [PMID: 33342463] - Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine, Vlado Perkovic, David C Wheeler. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 01; 77(1):23-34.e1. doi:
10.1053/j.ajkd.2020.06.018. [PMID: 32971190] - Daisuke Inoue, Hiroshi Nishi, Reiko Inoue, Masaomi Nangaku. Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
International heart journal.
2021; 62(3):592-600. doi:
10.1536/ihj.20-716. [PMID: 34054000] - Dimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, Konstantinos Imprialos, Michael Doumas. Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
The American journal of cardiology.
2021 01; 138(?):116-118. doi:
10.1016/j.amjcard.2020.10.007. [PMID: 33045203] - George Bakris, Megumi Oshima, Kenneth W Mahaffey, Rajiv Agarwal, Christopher P Cannon, George Capuano, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J L Heerspink, Adeera Levin, Bruce Neal, Richard Oh, Carol Pollock, Norman Rosenthal, David C Wheeler, Hong Zhang, Bernard Zinman, Meg J Jardine, Vlado Perkovic. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2020 12; 15(12):1705-1714. doi:
10.2215/cjn.10140620. [PMID: 33214158] - Sophia Zoungas, Kevan R Polkinghorne. Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?.
Clinical journal of the American Society of Nephrology : CJASN.
2020 12; 15(12):1694-1695. doi:
10.2215/cjn.16351020. [PMID: 33214159] - Megumi Oshima, Brendon L Neuen, JingWei Li, Vlado Perkovic, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Adeera Levin, Kenneth W Mahaffey, Luca De Nicola, Carol Pollock, Norman Rosenthal, David C Wheeler, Meg J Jardine, Hiddo J L Heerspink. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
Journal of the American Society of Nephrology : JASN.
2020 12; 31(12):2925-2936. doi:
10.1681/asn.2020050723. [PMID: 32998938] - Xuping Yang, Qinhui Liu, Yanping Li, Qin Tang, Tong Wu, Lei Chen, Shiyun Pu, Yingnan Zhao, Guorong Zhang, Cuiyuan Huang, Jinhang Zhang, Zijing Zhang, Ya Huang, Min Zou, Xiongjie Shi, Wei Jiang, Rui Wang, Jinhan He. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Adipocyte.
2020 12; 9(1):484-494. doi:
10.1080/21623945.2020.1807850. [PMID: 32835596] - Richard A Miller, David E Harrison, David B Allison, Molly Bogue, Lucas Debarba, Vivian Diaz, Elizabeth Fernandez, Andrzej Galecki, W Timothy Garvey, Hashan Jayarathne, Navasuja Kumar, Martin A Javors, Warren C Ladiges, Francesca Macchiarini, James Nelson, Peter Reifsnyder, Nadia A Rosenthal, Marianna Sadagurski, Adam B Salmon, Daniel L Smith, Jessica M Snyder, David B Lombard, Randy Strong. Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight.
2020 11; 5(21):. doi:
10.1172/jci.insight.140019. [PMID: 32990681] - Prawez Alam, Muzaffar Iqbal, Ahmed I Foudah, Mohammad H Alqarni, Faiyaz Shakeel. Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats.
Biomedical chromatography : BMC.
2020 Nov; 34(11):e4929. doi:
10.1002/bmc.4929. [PMID: 32579725] - Kazumi Mori-Anai, Yoshihiko Tashima, Tomohisa Nakada, Yoshinobu Nakamaru, Takayuki Takahata, Ryuta Saito. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Biopharmaceutics & drug disposition.
2020 Nov; 41(8-9):352-366. doi:
10.1002/bdd.2253. [PMID: 33085977] - Megumi Oshima, Brendon L Neuen, Meg J Jardine, George Bakris, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Bruce Neal, Carol Pollock, Norman Rosenthal, Takashi Wada, David C Wheeler, Vlado Perkovic, Hiddo J L Heerspink. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
The lancet. Diabetes & endocrinology.
2020 11; 8(11):903-914. doi:
10.1016/s2213-8587(20)30300-4. [PMID: 33065060] - Tejas Wattamwar, Ashish Mungantiwar, Supriya Gujar, Nancy Pandita. Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Oct; 1154(?):122281. doi:
10.1016/j.jchromb.2020.122281. [PMID: 32763846]